Literature DB >> 25459249

Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model.

Thomas F Scott1, Christopher T Hackett2, Matthew R Quigley3, Carol J Schramke1.   

Abstract

OBJECTIVE: To describe a "new natural history" of multiple sclerosis (MS), characterizing three patterns of progression in Relapsing MS (RMS) patients during the "treatment era," using newly developed definitions. By utilizing our simple model we intend to predict which patients are most likely to reach an EDSS of 6.0.
METHODS: We stratified MS progression into three distinct patterns: aggressive MS (AMS), intermediate MS (IMS) and mild MS (MMS), based on Expanded Disability Status Scale (EDSS) score rate of change. These groups were compared for progression of EDSS before and after reaching these definitions.
RESULTS: The three groups remained significantly different in terms of disability throughout their disease courses p ≤ 0.001; 98% of the patients used disease modifying treatments (DMTs). AMS patients represent a significantly more disabling and aggressive form of MS than the IMS group.
CONCLUSIONS: Transition from relatively mild MS to aggressive course may begin at any time in the first 15 years, despite DMTs. Our definition for AMS is unique and identifies a group of patients who become permanently disabled within two years after a variable amount of time in a benign phase, despite treatment with modern DMTs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aggressive; DMT; Multiple sclerosis; Natural history; Progression

Mesh:

Substances:

Year:  2014        PMID: 25459249     DOI: 10.1016/j.clineuro.2014.09.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 Years.

Authors:  Thomas F Scott; Troy Desai; Chris Hackett; Edward J Gettings; Teresa Hentosz; Wisam Elmalik; Carol J Schramke
Journal:  Int J MS Care       Date:  2019-12-05

Review 2.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.